________________________
Resources:
1 Silberstein, Stephen D. "Pharmacological Profile and Clinical Characteristics of Frovatriptan in the
Acute Treatment of Migraine." Headache: The Journal of Head and Face Pain 42 (s2), 45-46.
Available at:
http://dx.doi.org/10.1046/j.1526-4610.42.s2.1.x
2 Comer, M.B. & Hons. "Pharmacology of the Selective 5-HT1B/1D Agonist Frovatriptan."
Headache: The Journal of Head and Face Pain 42 (s2), 47-53.
Available at:
http://dx.doi.org/10.1046/j.1526-4610.42.s2.2.x
3 Buchan, P., Keywood, C., Wade, A. & Ward, C. "Clinical Pharmacokinetics of Frovatriptan."
Headache: The Journal of Head and Face Pain 42 (s2), 54-62.
Available at:
http://dx.doi.org/10.1046/j.1526-4610.42.s2.3.x
4 Buchan, P., Wade, A., Ward, C., Oliver, S.D., Mfpm, ,
Stewart, A.J. & Freestone, S. "Frovatriptan: A Review of Drug-Drug Interactions."
Headache: The Journal of Head and Face Pain 42 (s2), 63-73.
Available at:
http://dx.doi.org/10.1046/j.1526-4610.42.s2.4.x
5 Géraud, Gilles, Spierings, Egilius L.H. & Keywood,
Charlotte. "Tolerability and Safety of Frovatriptan With Short- and Long-term Use for
Treatment of Migraine and in Comparison With Sumatriptan." Headache: The Journal of Head and Face Pain 42 (s2), 93-99.
Available at:
http://dx.doi.org/10.1046/j.1526-4610.42.s2.7.x
